Tracheobronchial stenosis as a rare extraintestinal manifestation of ulcerativecolitis: a case series with different therapeutic approaches - Scorecard - MDSpire
Advertisement
Tracheobronchial stenosis as a rare extraintestinal manifestation of ulcerativecolitis: a case series with different therapeutic approaches
Clinical Scorecard: Tracheobronchial Stenosis: An Uncommon Extraintestinal Complication of Ulcerative Colitis Illustrated Through a Case Series and Various Treatment Strategies
At a Glance
Category
Detail
Condition
Tracheobronchial stenosis in ulcerative colitis
Key Mechanisms
Chronic lymphoplasmacytic infiltrates and mucosal edema
Target Population
Patients with ulcerative colitis
Care Setting
Multidisciplinary management in clinical settings
Key Highlights
Tracheobronchial stenosis is a rare but significant complication of ulcerative colitis.
Subclinical airway abnormalities may occur in 40–60% of ulcerative colitis cases.
Symptoms may develop years after initial ulcerative colitis diagnosis or during remission.
Management responses vary from active inflammation to irreversible fibrotic remodelling.
Multidisciplinary management is necessary due to the absence of standardised treatment protocols.
Guideline-Based Recommendations
Diagnosis
Early identification of tracheobronchial involvement is crucial.
Management
Individualised treatment incorporating medical therapy and interventional bronchoscopy.
Monitoring & Follow-up
Monitor for airway symptoms in patients with ulcerative colitis.
Risks
Potential for irreversible pulmonary damage if not addressed.
Patient & Prescribing Data
Female patients with ulcerative colitis experiencing bronchial stenosis.
Responses to treatment can vary significantly; corticosteroids and bronchoscopy may be required.
Clinical Best Practices
Consider bronchoscopy for patients unresponsive to systemic corticosteroids.
Assess airway symptoms regularly in patients with a history of ulcerative colitis.
Patients with chronic lung disease had numerically lower remission rates and substantially more serious adverse events in a 5-year Japanese registry study of late-onset rheumatoid arthritis.
